Helius Medical Technologies Inc (NASDAQ:HSDT) shares are trading higher after the Centers for Medicare & Medicaid Services assigned Healthcare Common Procedure Coding System (HCPCS) Level II codes A4593, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime” to describe the PoNS controller and A4594.
Helius Medical Technologies is a neurotech company in the medical device field focused on neurologic deficits. The company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS).
Helius Medical’s stock is trading higher on an increased session volume of 5.71 million, compared to the average volume of 171.2K, ...